Cell state gene expression signatures distinguish VEN and DORA sensitivities. (A) Spearman correlation of differential cell counts at the time of specimen collection with AUC for DORA, VEN, and the combination. Red-colored bars indicate no statistical significance. (B) Scatter and boxplots of sensitivities with respect to CD14 surface expression for matched samples from 105 AML unique patient samples displayed as AUC (% of maximum) for DORA, VEN, and the combination. (C) Normalized RNAseq-based gene expression levels for BCL2 and MAPK14 relative to surface expression of the monocytic marker CD14. Boxplots indicate the interquartile range. (D) Bar plot depicting log2 mean fold-change in expression for cell differentiation gene sets comparing sensitive (lowest quintile) and resistant (upper quintile) patient samples according to AUC distributions for DORA, VEN, and VEN+DORA. Significant false discovery rate–corrected P values for gene set enrichment are shown. BM, bone marrow; cDC, conventional dendritic cell; GMP, granulocyte-monocyte progenitor; HSC, hematopoietic stem cell; PB, peripheral blood; RBCs, red blood cells.